Stem Cell Transplant Linked to Longer Survival in CMML

Published Date: 12 Aug 2026

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

Read Full News

Latest News

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

News All Time

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Recommended News For You

Stem Cell Transplant Linked to Longer Survival in CMML

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

PSA Screening May Modestly Curb Prostate Cancer Deaths

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis

High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer

Recommended Articles For You

Neonatal Hematopoietic Transition and Blood Cell Maturation 

Hematology Laboratory Simulation: Advancing Clinical Competence through Technology-Driven Training 

RIBOTAC Therapy for Oncogenic RNA: A Paradigm Shift in Targeted Cancer Treatment 

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

2.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

3.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

4.

Tennessee Pharmacies Sell Potent Ivermectin Pushed by Anti-Vaccine Doctor

5.

Exercise can counter detrimental effects of cancer treatment, review suggests

1.

Toxicity Monitoring of Tumor-Targeted Degraders: Clinical Strategies and Emerging Evidence

2.

Tumor Ecosystem Profiles for Therapy Matching

3.

Early Detection of Breast Cancer: Signs, Symptoms, and Screening Methods

4.

The Power of Romiplostim in Treating Low Platelet Counts 

5.

Cancer Survivorship Services in Communities: Clinical Advances, Challenges, and the Path Forward

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

2.

Navigating the Complexities of Ph Negative ALL - Part XV

3.

Expert Perspectives on Hematology

4.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

5.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot